A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved ... The data with the CRISPR/Cas9 drug CTX001 is still very early-stage, coming from just seven thalassaemia ...

CRISPR Therapeutics and Vertex are also in the running with their gene-editing candidate CTX001, in phase 1/2 trials which are due to generate final results later this year. If those results are ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

Corient Private Wealth LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.0% during the fourth quarter, HoldingsChannel.com reports.The firm owned 8,827 shares ...

The Motley Fool has positions in and recommends CRISPR Therapeutics and Summit Therapeutics. The Motley Fool has a disclosure policy.

CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per ...

Shares of biotechnology stocks such as Recursion Pharmaceuticals (NASDAQ: RXRX), Summit Therapeutics (NASDAQ: SMMT), and CRISPR Therapeutics AG (NASDAQ: CRSP) plunged on Monday, down 9.4% ...

Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG. Novo is paying up to $1 ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has partnered with CRISPR Therapeutics to develop CASGEVY (exagamglogene autotemcel), a gene-edited cell therapy for sickle cell disease (SCD ...

Swedish biotech Asgard Therapeutics has brought Shane Olwill on board as chief development officer to help the company’s lead in vivo cell therapy ascend into clinical trials. Release > After ...

Back when he was himself working at Editas, Hunt rounded up executives from all the other major gene-editing companies working to bring the technology to patients — CRISPR Therapeutics ...